Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost

  • Lee, Jason Joon Bock (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Choi, Jinhyun (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Ahn, Sung Gwe (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Jeong, Joon (Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Lee, Ik Jae (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Park, Kwangwoo (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Kangpyo (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine) ;
  • Kim, Jun Won (Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Received : 2017.03.23
  • Accepted : 2017.05.22
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.

Keywords

References

  1. Njeh CF, Saunders MW, Langton CM. Accelerated partial breast irradiation (APBI): a review of available techniques. Radiat Oncol 2010;5:90. https://doi.org/10.1186/1748-717X-5-90
  2. Vaidya JS, Joseph DJ, Tobias JS, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010;376:91-102. https://doi.org/10.1016/S0140-6736(10)60837-9
  3. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74:987-1001. https://doi.org/10.1016/j.ijrobp.2009.02.031
  4. Chua BH, Henderson MA, Milner AD. Intraoperative radiotherapy in women with early breast cancer treated by breast-conserving therapy. ANZ J Surg 2011;81:65-9. https://doi.org/10.1111/j.1445-2197.2010.05431.x
  5. Kraus-Tiefenbacher U, Bauer L, Kehrer T, Hermann B, Melchert F, Wenz F. Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer: acute toxicity. Onkologie 2006;29:77-82.
  6. Blank E, Kraus-Tiefenbacher U, Welzel G, et al. Single-center long-term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage x-rays. Ann Surg Oncol 2010;17 Suppl 3:352-8. https://doi.org/10.1245/s10434-010-1265-z
  7. Veronesi U, Orecchia R, Luini A, et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res Treat 2010;124:141-51. https://doi.org/10.1007/s10549-010-1115-5
  8. Benda RK, Yasuda G, Sethi A, Gabram SG, Hinerman RW, Mendenhall NP. Breast boost: are we missing the target? Cancer 2003;97:905-9. https://doi.org/10.1002/cncr.11142
  9. Holmes DR. Intraoperative radiotherapy in breast conserving surgery. J Surg Oncol 2014;110:68-74. https://doi.org/10.1002/jso.23620
  10. Silverstein MJ, Fastner G, Maluta S, et al. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 1. ELIOT. Ann Surg Oncol 2014;21:3787-92. https://doi.org/10.1245/s10434-014-3998-6
  11. Hepel J, Wazer DE. A flawed study should not define a new standard of care. Int J Radiat Oncol Biol Phys 2015;91:255-7. https://doi.org/10.1016/j.ijrobp.2014.09.019
  12. Silverstein MJ, Fastner G, Maluta S, et al. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 2. TARGIT. Ann Surg Oncol 2014;21:3793-9. https://doi.org/10.1245/s10434-014-3999-5
  13. Vaidya JS, Baum M, Tobias JS, et al. Long-term results of targeted intraoperative radiotherapy (TARGIT) boost during breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011;81:1091-7. https://doi.org/10.1016/j.ijrobp.2010.07.1996
  14. Anderson JD, Chandler SC, Mason MA, et al. Scientific analysis reveals major differences in the breast size of women in different countries. J Female Health Sci [Internet]. JFH. TD.13.098 [cited 2017 May 25]. Available from: http://www.sciencedatabaseonline.org/ADB1/Scientific%20Article%20JOFHS.pdf.
  15. Patel PS, Yan W, Trichter S, et al. Seroma is an expected consequence and not a complication of MammoSite brachytherapy. Breast J 2011;17:498-502. https://doi.org/10.1111/j.1524-4741.2011.01127.x
  16. Kraus-Tiefenbacher U, Welzel G, Brade J, et al. Postoperative seroma formation after intraoperative radiotherapy using lowkilovoltage X-rays given during breast-conserving surgery. Int J Radiat Oncol Biol Phys 2010;77:1140-5. https://doi.org/10.1016/j.ijrobp.2009.06.008
  17. Cracco S, Semprini G, Cattin F, et al. Impact of intraoperative radiotherapy on cosmetic outcome and complications after oncoplastic breast surgery. Breast J 2015;21:285-90. https://doi.org/10.1111/tbj.12402
  18. Sharma R, Jursinic PA. In vivo measurements for high dose rate brachytherapy with optically stimulated luminescent dosimeters. Med Phys 2013;40:071730. https://doi.org/10.1118/1.4811143
  19. Sawaki M, Kondo N, Horio A, et al. Feasibility of intraoperative radiation therapy for early breast cancer in Japan: a singlecenter pilot study and literature review. Breast Cancer 2014;21:415-22. https://doi.org/10.1007/s12282-012-0412-8

Cited by

  1. Malignant and borderline phyllodes tumors of the breast: a multicenter study of 362 patients (KROG 16-08) vol.171, pp.2, 2018, https://doi.org/10.1007/s10549-018-4838-3
  2. Skin dose assessment with treatment planning system (TPS) and skin reaction evaluation of early breast cancer patients treated via an intraoperative radiation therapy (IORT) device vol.17, pp.4, 2017, https://doi.org/10.1017/s1460396918000237
  3. A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients vol.174, pp.1, 2019, https://doi.org/10.1007/s10549-018-5038-x
  4. Prediction of skin dose in low-kV intraoperative radiotherapy using machine learning models trained on results ofin vivodosimetry vol.46, pp.3, 2019, https://doi.org/10.1002/mp.13379
  5. Redefining Eligibility by Analyzing Canceled Intraoperative Radiotherapy as a Boost for Patients Undergoing Breast-Conserving Treatment vol.26, pp.13, 2017, https://doi.org/10.1245/s10434-019-07819-5
  6. Complications and local relapse after intraoperative low-voltage X-ray radiotherapy in breast cancer vol.98, pp.6, 2017, https://doi.org/10.4174/astr.2020.98.6.299
  7. Patient-Specific Quality Assurance Using a 3D-Printed Chest Phantom for Intraoperative Radiotherapy in Breast Cancer vol.11, pp.None, 2017, https://doi.org/10.3389/fonc.2021.629927
  8. Evaluation of skin dose and skin toxicity in patients undergoing intraoperative radiotherapy for early breast cancer vol.22, pp.8, 2021, https://doi.org/10.1002/acm2.13338
  9. Complication Rates After Intraoperative Radiation Therapy: Do Applicator Size and Distance to Skin Matter? vol.268, pp.None, 2017, https://doi.org/10.1016/j.jss.2021.06.078